Eli Lilly’s mirikizumab shows promise in Phase III Crohn’s disease trial

Eli Lilly has reported promising results from the Phase III VIVID-1 study of mirikizumab in treating moderately to severely active Crohn’s disease.

The randomised, treat-through, double-blind trial assessed the safety and efficacy of mirikizumab versus placebo and ustekinumab, an active control.